MDxHealth expects to be key Dutch provider of urine-based prostate cancer testing
This article was originally published in Clinica
Executive Summary
MDxHealth has launched a new liquid biopsy prostate cancer test, SelectMDx, in Europe, a month after gaining the technology through the acquisition of its developer NovioGendix. The test will be offered through NovioGendix’s lab facilities in Nijmegen, the Netherlands, which MDxHealth also acquired.
You may also be interested in...
MDxHealth Gears Up For Major EU Growth
Cancer diagnostics company MDxHealth is poised for more commercial growth in 2018 following a move to larger lab facilities in Nijmegen, the Netherlands. The move is part of the company's strategy to grow commercialization of its SelectMDx prostate cancer test in Europe and conduct additional R&D activities.
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.